APO RESEARCH · REPORT
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Product & engineering
Understand the product.
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Selected research
Market Outlook & Growth Opportunities
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Outlook and Growth Opportunities 2026
Market perspective
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.
North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.
Read the full market overview
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.
This report provides an overview of the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Chemotherapy Induced Nausea and Vomiting (CINV) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Company
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Application
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Chemotherapy Induced Nausea and Vomiting (CINV) Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Chemotherapy Induced Nausea and Vomiting (CINV) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs industry.
Chapter 3: Detailed analysis of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- 5-HT3 Inhibitors
- NK1 Inhibitors
- Other
Applications
- Highly Emetogenic Chemotherapy
- Moderately Emetogenic Chemotherapy
- Low Emetogenic Chemotherapy
- Other
Companies covered
- Merck
- Eisai
- Mundipharma
- Qilu Pharma
- Teva
- Novartis
- Heron Therapeutics
- Roche
- Mylan
- Tesaro
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value (2021-2032)
- 1.2.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume (2021-2032)
- 1.2.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Dynamics
- 2.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Trends
- 2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Drivers
- 2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Opportunities and Challenges
- 2.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Restraints
3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by Company
- 3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Company Revenue Ranking in 2025
- 3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue by Company (2021-2026)
- 3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Company (2021-2026)
- 3.4 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Average Price by Company (2021-2026)
- 3.5 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Company Ranking (2024-2026)
- 3.6 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Company Manufacturing Base and Headquarters
- 3.7 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Company Product Type and Application
- 3.8 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by Type
- 4.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Type Introduction
- 4.1.1 5-HT3 Inhibitors
- 4.1.2 NK1 Inhibitors
- 4.1.3 Other
- 4.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Type
- 4.2.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Type (2021-2032)
- 4.2.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume Share by Type (2021-2032)
- 4.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Type
- 4.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Type (2021-2032)
- 4.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type (2021-2032)
5 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by Application
- 5.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Application Introduction
- 5.1.1 Highly Emetogenic Chemotherapy
- 5.1.2 Moderately Emetogenic Chemotherapy
- 5.1.3 Low Emetogenic Chemotherapy
- 5.1.4 Other
- 5.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Application
- 5.2.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume by Application (2021-2032)
- 5.2.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Volume Share by Application (2021-2032)
- 5.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Application
- 5.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Application (2021-2032)
- 5.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application (2021-2032)
6 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Regional Sales and Value Analysis
- 6.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Region (2021-2032)
- 6.2.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Region: 2021-2026
- 6.2.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Region (2027-2032)
- 6.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Region (2021-2032)
- 6.4.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Region: 2021-2026
- 6.4.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Region (2027-2032)
- 6.5 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value (2021-2032)
- 6.6.2 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value (2021-2032)
- 6.7.2 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value (2021-2032)
- 6.9.2 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Country, 2025 VS 2032
7 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Country-level Sales and Value Analysis
- 7.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Country (2021-2032)
- 7.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Country (2021-2026)
- 7.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales by Country (2027-2032)
- 7.4 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Country (2021-2032)
- 7.4.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Country (2021-2026)
- 7.4.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.9.2 France Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.16.2 China Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.19.2 India Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Merck
- 8.1.1 Merck Company Information
- 8.1.2 Merck Business Overview
- 8.1.3 Merck Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Merck Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.1.5 Merck Recent Developments
- 8.2 Eisai
- 8.2.1 Eisai Company Information
- 8.2.2 Eisai Business Overview
- 8.2.3 Eisai Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Eisai Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.2.5 Eisai Recent Developments
- 8.3 Mundipharma
- 8.3.1 Mundipharma Company Information
- 8.3.2 Mundipharma Business Overview
- 8.3.3 Mundipharma Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Mundipharma Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.3.5 Mundipharma Recent Developments
- 8.4 Qilu Pharma
- 8.4.1 Qilu Pharma Company Information
- 8.4.2 Qilu Pharma Business Overview
- 8.4.3 Qilu Pharma Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Qilu Pharma Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.4.5 Qilu Pharma Recent Developments
- 8.5 Teva
- 8.5.1 Teva Company Information
- 8.5.2 Teva Business Overview
- 8.5.3 Teva Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Teva Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.5.5 Teva Recent Developments
- 8.6 Novartis
- 8.6.1 Novartis Company Information
- 8.6.2 Novartis Business Overview
- 8.6.3 Novartis Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Novartis Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.6.5 Novartis Recent Developments
- 8.7 Heron Therapeutics
- 8.7.1 Heron Therapeutics Company Information
- 8.7.2 Heron Therapeutics Business Overview
- 8.7.3 Heron Therapeutics Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Heron Therapeutics Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.7.5 Heron Therapeutics Recent Developments
- 8.8 Roche
- 8.8.1 Roche Company Information
- 8.8.2 Roche Business Overview
- 8.8.3 Roche Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Roche Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.8.5 Roche Recent Developments
- 8.9 Mylan
- 8.9.1 Mylan Company Information
- 8.9.2 Mylan Business Overview
- 8.9.3 Mylan Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Mylan Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.9.5 Mylan Recent Developments
- 8.10 Tesaro
- 8.10.1 Tesaro Company Information
- 8.10.2 Tesaro Business Overview
- 8.10.3 Tesaro Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Tesaro Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Product Portfolio
- 8.10.5 Tesaro Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Value Chain Analysis
- 9.1.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Mode & Process
- 9.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Distributors
- 9.2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst